ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY


Associated tags: UNITE, Biotechnology, Oncology, Infection, University, Health, Pharmaceutical industry, Therapy, Allergy, Degenerative disease, History, ITI, Vaccine, CMV, LAMP, Patient, GBM, Research, Science, Patent

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2022

Retrieved on: 
Thursday, April 14, 2022
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, Patent, Cancer, GBM, Glioblastoma, Survival, Brain, Immunomics, Patient, Infection, Congress, CMV, UNITE, Company, Vaccine, ITI, Antigen, Immune system, History, Degenerative disease, Neoplasm, LAMP, Allergy, Therapy, Pharmaceutical industry

Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the World Vaccine Congress in Washington, DC being held April 18-21, 2022.

Key Points: 
  • Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today that the company will be presenting at the World Vaccine Congress in Washington, DC being held April 18-21, 2022.
  • CEO and Founder Bill Hearl, Ph.D., will present a talk titled, Clinical Updates on Autologous Dendritic Cell Vaccines for Solid Tumors, at 10:10AM EDT on April 21, 2022.
  • Presentation details are as follows:
    ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM.
  • ITI-1000 was developed using Immunomics proprietary investigational lysosomal targeting technology, UNITE, in the context of cell therapy.

Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical Study of CMV RNA-Pulsed Dendritic Cell Vaccine for the Treatment of Newly-Diagnosed Glioblastoma Patients

Retrieved on: 
Tuesday, November 30, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Clinical Trials, Other Health, World Health Organization, ITI, Death, GBM, Company, Lysosome-associated membrane glycoprotein, Diagnosis, WHO, History, DNA, B cell, Biotechnology, Allergy, Infection, UNITE, Brain, Glioblastoma, World, Cancer, Acute myeloid leukemia, University, LAMP1, The Society of Neurological Surgeons, American Association of Neurological Surgeons, Duane Mitchell, Trial of the century, Degenerative disease, Partnership, American Brain Tumor Association, Human, Temozolomide, Vaccine, Survival, Adult, ATTAC, Therapy, American Association, Association, Patient, Duke University School of Medicine, LAMP, Duke University, Chemoradiotherapy, Antigen presentation, Astellas Pharma, Patent, Immunomics, RNA, Astrocyte, DC, CMV, Pharmaceutical industry, Glioblastoma (GBM), ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., GLIOBLASTOMA (GBM), ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.

Key Points: 
  • This is an extension of the Phase 2 ATTAC-II study ( NCT02465268 ) where eligibility is limited to those patients who have had surgery but have not yet received chemoradiation.
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • This dendritic cell vaccine is then returned to the patient.
  • The ATTAC-II study ( NCT02465268 ) is a Phase II randomized, placebo-controlled clinical trial enrolling patients with newly diagnosed GBM that will explore whether dendritic cell (DC) vaccines, including ITI-1000, targeting the CMV antigen pp65 improves survival.

Immunomic Therapeutics Presents Clinical Data From ATTAC Studies in GBM at the 2021 Society for Neurology (SNO) Annual Meeting

Retrieved on: 
Thursday, November 18, 2021
Research, Clinical Trials, Biotechnology, Health, University, Pharmaceutical, Science, Education, Oncology, Patient, Degenerative disease, Cancer, ITI, Company, Duke University School of Medicine, GBM, Lysosome-associated membrane glycoprotein, MD, Glioblastoma, LAMP, LTD, Acute myeloid leukemia, Human, University, Duke University, Vaccination, Vaccine, History, Annual general meeting, Survival, DNA, Phase, Patent, Biotechnology, Immunomics, SNO, RNA, Allergy, Infection, Therapy, Multimedia, The Society of Neurological Surgeons, UNITE, CMV, Pharmaceutical industry, ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc., ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, UNITE, IMMUNOMIC THERAPEUTICS, INC.

The Phase II ATTAC study ( NCT00639639 ) led to an expanded cohort trial (ATTAC-GM: NCT00693639 ) resulting in positive immunologic and clinical response.

Key Points: 
  • The Phase II ATTAC study ( NCT00639639 ) led to an expanded cohort trial (ATTAC-GM: NCT00693639 ) resulting in positive immunologic and clinical response.
  • The larger confirmatory trial, ELEVATE ( NCT02366728 ), revealed significantly longer overall survival (OS) in patients randomized to LAMP pp65 RNA loaded DC vaccines combined with tetanus-diphtheria booster.
  • The results demonstrate that a CMV pp65-LAMP RNA-pulsed dendritic cell vaccination was associated with positive immunologic and clinical response in patients with glioblastoma (GBM).
  • ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM.

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2021

Retrieved on: 
Tuesday, April 27, 2021
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccine, Allergy, UNITE, ITI-1000 and the Phase 2 (ATTAC-II) Study, Immunomic Therapeutics, Inc., UNITE, ITI-1000 AND THE PHASE 2 (ATTAC-II) STUDY, IMMUNOMIC THERAPEUTICS, INC.

b'Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021.

Key Points: 
  • b'Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually May 4-6, 2021.
  • This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases.
  • In May 2017, Immunomic exclusively licensed a patent portfolio from Annias Immunotherapeutics for use in combination with UNITE and ITI-1000, allowing Immunomic to combine UNITE with a patented and proprietary CMV immunotherapy platform.
  • The UNITE platform has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases.

Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2020

Retrieved on: 
Monday, September 14, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Infectious diseases, Clinical medicine, RTT, Vaccines, Vaccination, Vaccine, Virology, Measles, UNITE, ITI-1000 and the Phase 2 (ATTAC-II) Study, Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020.

Key Points: 
  • Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020.
  • Vaccines are one of the safest, most widely-adopted health care practices in the world.
  • One example is Measles, which can have a lasting impact on a childs immune system, said Dr. William Hearl, Why We Vax Chairman, Immunomic Therapeutics CEO, and experienced vaccinologist.
  • The World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speakers, exclusive interviews, world leading presentations, live panel debates, and virtual face to face meetings.

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM

Retrieved on: 
Tuesday, September 1, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer, Vaccine, Virology, Dendritic cell, Glioblastoma, Draft:Duane A. Mitchell, Tumor antigen vaccine, Glioblastoma (GBM), ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc.

ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.

Key Points: 
  • ITIs dendritic cell vaccine is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • The published results from the three original ATTAC clinical studies are summarized below:
    Three separate clinical trials conducted by Drs.
  • Mitchell and Sampson utilized Cytomegalovirus specific dendritic cell vaccines in patients with newly diagnosed glioblastoma.
  • I look forward to continued evaluation of ITIs dendritic cell vaccines, including ITI-1000, in the ongoing, randomized, placebo-controlled ATTAC-II study.

Immunomic Therapeutics Assumes Sponsorship of ATTAC-II IND for ITI-1000, a Dendritic Cell Vaccine in Phase 2 for the Treatment of GBM

Retrieved on: 
Tuesday, October 1, 2019
Biotechnology, Pharmaceutical, Oncology, Health, General Health, Clinical trials, RTT, Medicine, Clinical medicine, Cancer, Glioblastoma, Oncology, Brain tumor, Northwest Biotherapeutics, ITI-1000 and the Phase 2 (ATTAC-II) Study, UNITE, Immunomic Therapeutics, Inc.

ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of the aggressive brain tumor, Glioblastoma Multiforme (GBM).

Key Points: 
  • ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of the aggressive brain tumor, Glioblastoma Multiforme (GBM).
  • ITI-1000 is designed to target the pp65 viral antigen of Cytomegalovirus (CMV) that is expressed in GBM, but not in normal brain cells.
  • We are very excited to lead the clinical development of ITI-1000 and assume responsibilities of the ATTAC-II study in GBM, said Dr. William Hearl, CEO of Immunomic Therapeutics.
  • ITI-1000 is an investigational dendritic cell vaccine therapy currently in a Phase 2 clinical trial (ATTAC-II) for the treatment of GBM.